Anders Hostrup Larsen1,2, Henrik Wiggers1, Ole Lindgård Dollerup2,3, Nichlas Riise Jespersen1, Nils Henrik Hansson1, Jørgen Frøkiær4, Kim Brøsen5, Helene Nørrelund6, Hans Erik Bøtker1, Niels Møller2,7, Niels Jessen8,9,10. 1. Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark. 2. Department of Clinical Medicine, Medical Research Laboratory, Aarhus University Hospital, Aarhus, Denmark. 3. Faculty of Health and Medical Sciences, Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark. 4. Department of Nuclear Medicine and PET Centre, Aarhus University Hospital, Aarhus, Denmark. 5. Department of Clinical Pharmacology, University of Southern Denmark, Odense C, Denmark. 6. Department of Clinical Epidemiology, Institute of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark. 7. Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark. 8. Department of Clinical Pharmacology, Aarhus University Hospital, Aarhus, Denmark. niels.jessen@biomed.au.dk. 9. Department of Biomedicine, Aarhus University, Aarhus, Denmark. niels.jessen@biomed.au.dk. 10. Steno Diabetes Centre Aarhus, Aarhus University Hospital, Hedeager 3, DK-8200, Aarhus N, Denmark. niels.jessen@biomed.au.dk.
Abstract
PURPOSE: The glucose-lowering drug metformin has recently been shown to reduce myocardial oxygen consumption and increase myocardial efficiency in chronic heart failure (HF) patients without diabetes. However, it remains to be established whether these beneficial myocardial effects are associated with metformin-induced alterations in whole-body insulin sensitivity and substrate metabolism. METHODS: Eighteen HF patients with reduced ejection fraction and without diabetes (median age, 65 (interquartile range 55-68); ejection fraction 39 ± 6%; HbA1c 5.5 to 6.4%) were randomized to receive metformin (n = 10) or placebo (n = 8) for 3 months. We studied the effects of metformin on whole-body insulin sensitivity using a two-step hyperinsulinemic euglycemic clamp incorporating isotope-labeled tracers of glucose, palmitate, and urea. Substrate metabolism and skeletal muscle mitochondrial respiratory capacity were determined by indirect calorimetry and high-resolution respirometry, and body composition was assessed by bioelectrical impedance analysis. The primary outcome measure was change in insulin sensitivity. RESULTS: Compared with placebo, metformin treatment lowered mean glycated hemoglobin levels (absolute mean difference, - 0.2%; 95% CI - 0.3 to 0.0; p = 0.03), reduced body weight (- 2.8 kg; 95% CI - 5.0 to - 0.6; p = 0.02), and increased fasting glucagon levels (3.2 pmol L-1; 95% CI 0.4 to 6.0; p = 0.03). No changes were observed in whole-body insulin sensitivity, endogenous glucose production, and peripheral glucose disposal or oxidation with metformin. Equally, resting energy expenditure, lipid and urea turnover, and skeletal muscle mitochondrial respiratory capacity remained unaltered. CONCLUSION: Increased myocardial efficiency during metformin treatment is not mediated through improvements in insulin action in HF patients without diabetes. CLINICAL TRIAL REGISTRATION: URL: https://clinicaltrials.gov . Unique identifier: NCT02810132. Date of registration: June 22, 2016.
PURPOSE: The glucose-lowering drug metformin has recently been shown to reduce myocardial oxygen consumption and increase myocardial efficiency in chronic heart failure (HF) patients without diabetes. However, it remains to be established whether these beneficial myocardial effects are associated with metformin-induced alterations in whole-body insulin sensitivity and substrate metabolism. METHODS: Eighteen HF patients with reduced ejection fraction and without diabetes (median age, 65 (interquartile range 55-68); ejection fraction 39 ± 6%; HbA1c 5.5 to 6.4%) were randomized to receive metformin (n = 10) or placebo (n = 8) for 3 months. We studied the effects of metformin on whole-body insulin sensitivity using a two-step hyperinsulinemic euglycemic clamp incorporating isotope-labeled tracers of glucose, palmitate, and urea. Substrate metabolism and skeletal muscle mitochondrial respiratory capacity were determined by indirect calorimetry and high-resolution respirometry, and body composition was assessed by bioelectrical impedance analysis. The primary outcome measure was change in insulin sensitivity. RESULTS: Compared with placebo, metformin treatment lowered mean glycated hemoglobin levels (absolute mean difference, - 0.2%; 95% CI - 0.3 to 0.0; p = 0.03), reduced body weight (- 2.8 kg; 95% CI - 5.0 to - 0.6; p = 0.02), and increased fasting glucagon levels (3.2 pmol L-1; 95% CI 0.4 to 6.0; p = 0.03). No changes were observed in whole-body insulin sensitivity, endogenous glucose production, and peripheral glucose disposal or oxidation with metformin. Equally, resting energy expenditure, lipid and urea turnover, and skeletal muscle mitochondrial respiratory capacity remained unaltered. CONCLUSION: Increased myocardial efficiency during metformin treatment is not mediated through improvements in insulin action in HF patients without diabetes. CLINICAL TRIAL REGISTRATION: URL: https://clinicaltrials.gov . Unique identifier: NCT02810132. Date of registration: June 22, 2016.
Authors: William C Knowler; Elizabeth Barrett-Connor; Sarah E Fowler; Richard F Hamman; John M Lachin; Elizabeth A Walker; David M Nathan Journal: N Engl J Med Date: 2002-02-07 Impact factor: 91.245
Authors: G Zhou; R Myers; Y Li; Y Chen; X Shen; J Fenyk-Melody; M Wu; J Ventre; T Doebber; N Fujii; N Musi; M F Hirshman; L J Goodyear; D E Moller Journal: J Clin Invest Date: 2001-10 Impact factor: 14.808
Authors: David Preiss; Suzanne M Lloyd; Ian Ford; John J McMurray; Rury R Holman; Paul Welsh; Miles Fisher; Chris J Packard; Naveed Sattar Journal: Lancet Diabetes Endocrinol Date: 2013-11-07 Impact factor: 32.069
Authors: Ole L Dollerup; Britt Christensen; Mads Svart; Mark S Schmidt; Karolina Sulek; Steffen Ringgaard; Hans Stødkilde-Jørgensen; Niels Møller; Charles Brenner; Jonas T Treebak; Niels Jessen Journal: Am J Clin Nutr Date: 2018-08-01 Impact factor: 7.045
Authors: Anila K Madiraju; Derek M Erion; Yasmeen Rahimi; Xian-Man Zhang; Demetrios T Braddock; Ronald A Albright; Brett J Prigaro; John L Wood; Sanjay Bhanot; Michael J MacDonald; Michael J Jurczak; Joao-Paulo Camporez; Hui-Young Lee; Gary W Cline; Varman T Samuel; Richard G Kibbey; Gerald I Shulman Journal: Nature Date: 2014-05-21 Impact factor: 49.962
Authors: Roger W Hunter; Curtis C Hughey; Louise Lantier; Elias I Sundelin; Mark Peggie; Elton Zeqiraj; Frank Sicheri; Niels Jessen; David H Wasserman; Kei Sakamoto Journal: Nat Med Date: 2018-08-27 Impact factor: 53.440